Perspective Therapeutics, Inc. (CATX) stock
CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Perspective Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Perspective Therapeutics's gross margin for the twelve months ending Jun 30, 2022 was 0.0%. For fiscal 2022 it was 0.0%, against 50.9% the year before. The highest annual figure on record is 52.9% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | 0.0% | −50.9 |
| FY2021 | Jun 30, 2021 | 50.9% | −2.0 |
| FY2020 | Jun 30, 2020 | 52.9% | +11.3 |
| FY2019 | Jun 30, 2019 | 41.7% | +10.6 |
| FY2018 | Jun 30, 2018 | 31.1% | +13.5 |
| FY2017 | Jun 30, 2017 | 17.6% | +14.9 |
| FY2016 | Jun 30, 2016 | 2.7% | −0.9 |
| FY2015 | Jun 30, 2015 | 3.6% | +8.3 |
| FY2014 | Jun 30, 2014 | -4.7% | −8.0 |
| FY2013 | Jun 30, 2013 | 3.3% | −10.5 |
| FY2012 | Jun 30, 2012 | 13.9% | −8.2 |
| FY2011 | Jun 30, 2011 | 22.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | 37.0% | −12.7 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 49.5% | −2.9 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | 43.3% | −6.1 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | 40.1% | −12.1 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | 49.7% | +2.7 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | 52.4% | −6.9 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | 49.5% | −0.9 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | 52.3% | −1.1 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | 47.0% | +1.3 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | 59.2% | +13.6 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | 50.4% | +10.2 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | 53.4% | +19.8 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | 45.7% | +18.1 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | 45.7% | +7.0 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | 40.2% | +5.6 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | 33.5% | +11.7 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | 27.6% | −8.7 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | 38.7% | +15.9 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 34.6% | +34.7 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | 21.9% | +17.4 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | 36.4% | +40.6 |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | 22.9% | +17.3 |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -0.1% | −2.6 |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | 4.4% | −2.1 |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -4.3% | −19.6 |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | 5.5% | +0.7 |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | 2.5% | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | 6.6% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | 15.3% | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | 4.8% | – |
See a number that looks wrong?